Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc has announced significant advancements with its Parsortix system in analyzing gene expression in metastatic prostate cancer (mPCa) patients. A study by the Medical University of Innsbruck revealed that Parsortix successfully isolated circulating tumor cells (CTCs) in 80% of patients, offering a viable alternative when tissue biopsies are not possible. Longitudinal monitoring indicated a drop in CTCs correlating with positive drug responses, further underscoring its potential for pharma services. With approximately 3.2 million U.S. men living with prostate cancer, these findings may guide personalized treatment decisions.
ANGLE plc (OTCQX:ANPCY) will release its interim results for the six months ending June 30, 2021, on September 30, 2021. A virtual meeting for analysts starts at 10:00 AM BST the same day. Registration is required to attend the webcast, which serves as a watch-only platform with Q&A reserved for analysts. ANGLE is a leader in liquid biopsy, known for its Parsortix technology enabling non-invasive cancer cell analysis. The company aims for FDA clearance for CTC harvesting, which could elevate its market position significantly.
ANGLE plc has announced the allotment of 500,000 new ordinary shares following the exercise of share options by Finance Director Ian Griffiths at £0.2575 each. This transaction boosts Griffiths' holdings to 1,203,832 shares, approximately 0.5% of issued share capital. Application for the shares' trading admission will be made, with an expected effective date of August 27, 2021. Post-admission, the total number of ordinary shares will be 234,848,051, which shareholders can use to calculate their interest changes under FCA regulations.
ANGLE plc announced a study from the Institute of Oncology, Slovenia that demonstrates the superior performance of its Parsortix system in harvesting circulating tumor cells (CTCs) from metastatic breast cancer patients. The study highlighted that 64% of patients yielded CTCs using Parsortix compared to 57% with an antibody-based system. The Parsortix method also preserved the morphology of 99% of the isolated cells, enhancing quality and analysis potential. This positions Parsortix for routine integration in clinical laboratories, addressing the need for non-invasive biopsy options for patients.
ANGLE plc (OTCQX:ANPCY) announced the issuance of 140,000 new ordinary shares following the exercise of employee options. The new shares will rank equally with existing shares and are set to be admitted to trading on AIM on August 12, 2021. Post-admission, the total number of ordinary shares in issue will be 234,348,051. This move is part of the company's ongoing strategy to enhance its capital structure and support its liquid biopsy technologies, which have demonstrated promising clinical results in cancer diagnostics.
ANGLE plc (OTCQX:ANPCY) has issued 26,667 new ordinary shares following the exercise of employee options, increasing the total shares to 234,208,051. The new shares will begin trading on the London Stock Exchange on 9 August 2021. ANGLE is renowned for its liquid biopsy technology, the Parsortix system, which allows non-invasive cancer cell analysis and has shown significant accuracy in clinical studies, particularly for ovarian cancer. The company is pursuing FDA clearance for its system, aiming to enhance its market position in oncology diagnostics.
ANGLE plc has secured a pharma services contract for developing two custom CTC assays targeting DNA damage repair biomarkers. The contract, valued at approximately US$ 400,000, involves developing assays for four challenging cancers: triple negative breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer. The initial phase will provide significant revenue and, if successful, will lead to further clinical trials planned for H2 2022. The assays will enhance ANGLE's service offerings to pharma clients by enabling targeted analysis on circulating tumor cells.
ANGLE plc (OTCQX:ANPCY) announces significant advancements using its Parsortix system to isolate circulating tumor cells (CTCs) from patients with brain metastasis. This breakthrough offers a non-invasive alternative to traditional tissue biopsies for patients with breast cancer, non-small cell lung cancer, and melanoma, achieving 50% CTC positivity rates in breast and NSCLC patients, outperforming previous technologies. With approximately 200,000 new brain metastasis cases in the US annually, this method could enhance personalized treatment decisions and improve patient outcomes.
ANGLE plc announces the allotment of 1,023,826 new ordinary shares following the exercise of options by CEO Andrew Newland. The shares were sold at 125 pence each for personal financial reasons. After the sale, Newland retains 7,054,686 shares, equating to 3.0% of the total issued share capital, alongside options for an additional 3,000,000 shares and up to 5,400,000 through performance plans. The total number of shares in issue will rise to 234,181,384 upon the new shares' admission on July 14, 2021.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leader in liquid biopsy technology, has issued 48,333 new Ordinary shares due to employee option exercises. This issuance increases the total shares to 233,157,558, enhancing voting rights. The shares are expected to be admitted to trading on the London Stock Exchange on July 7, 2021. ANGLE's Parsortix technology continues to gain traction, with ongoing FDA submission for CTC analysis in breast cancer and strong clinical performance in ovarian cancer diagnostics.